Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.

[1]  S. Mok,et al.  Pathogenesis and Clinical Management of Uterine Serous Carcinoma , 2020, Cancers.

[2]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[4]  B. Monk,et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.

[5]  M. Morgan,et al.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. , 2019, The New England journal of medicine.

[6]  F. Couch,et al.  Cancer susceptibility gene mutations in type I and II endometrial cancer. , 2019, Gynecologic oncology.

[7]  B. Job,et al.  Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas , 2018, Clinical Cancer Research.

[8]  B. Gilks,et al.  Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes , 2018, British Journal of Cancer.

[9]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[10]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[11]  A. Secord,et al.  Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  James X. Sun,et al.  Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC). , 2017 .

[13]  O. Dekkers,et al.  Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. , 2017, European journal of cancer.

[14]  A. Santin,et al.  Targeted therapy in the treatment of uterine serous carcinoma. , 2015, Pharmacogenomics.

[15]  Joshua M. Stuart,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[16]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[17]  Rochelle L. Garcia,et al.  BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma , 2013, Cancer.

[18]  M. Birrer,et al.  Uterine papillary serous cancer: a review of the literature. , 2012, Gynecologic oncology.

[19]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[20]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[21]  M. Hendrickson,et al.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.

[22]  R. Broaddus,et al.  Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. , 2003, Gynecologic oncology.

[23]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[24]  J. Berek,et al.  Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.